Have a Look at Hedge Funds’ Recent Moves in These Three Stocks

Another 13G recently filed with the SEC reveals that Steve Cohen’s Point72 Asset Management L.P. owns 5.38 million shares of Constellium NV (NYSE:CSTM), representing 5.1% of the company’s shares. This denotes an increase of 4.85 million shares from the fund’s position revealed via its 13F filing for the period of September 30. The shares of the Netherlands-based producer of aluminium semi-products have lost 49% in 2015, but have embarked on a steady uptrend since the beginning of November. Earlier this month, the company reported third quarter revenues of $1.41 billion, which were up by 36% year-over-year, but missed analysts’ estimates of $1.46 billion. Constellium reported a net loss of $0.48 per share, while analysts had anticipated net earnings per share of $0.06.

Meanwhile, 25 hedge funds tracked by Insider Monkey had positions in Constellium NV (NYSE:CSTM) at the end of the June quarter, one fund less quarter-over-quarter. The value of the stakes also declined to $390.37 million from $463.30 million during the three-month period. It is also worth pointing out that these 25 investors owned 31.50% of Constellium’s common stock on June 30. Phill Gross and Robert Atchinson’s Adage Capital Management upped its stake in Constellium NV (NYSE:CSTM) by 988,022 shares during the latest quarter to 9.31 million shares.

According to a Schedule 13G filing, Christopher Medlock James’ Partner Fund Management L.P. recently acquired a 1.52 million-share stake in Kura Oncology Inc. (NASDAQ:KURA), which accounts for 7.2% of the company’s outstanding common stock. Just recently, the clinical stage biopharmaceutical company uplisted from the OTCQB venture marketplace to the NASDAQ Global Select Market. However, the stock lost slightly over 7% in today’s trading session, which could somewhat suggest that investors are not overly excited about the company’s future potential.

Kura Oncology Inc. (NASDAQ:KURA) focuses on discovering and developing personalized therapeutics aimed at treating solid tumors and blood cancers. In May 2015, Kura Oncology initiated a Phase II clinical trial on its lead product candidate, tipifarnib, in patients who have solid tumors with HRAS mutations. It is worth pointing out that the company is anticipated to incur losses over the next several years and it does not have any approved products, which could make a potential investment in the company quite risky.

Disclosure: None